Dietrich Eric, Davis Kyle
University of Florida College of Medicine, Gainesville, FL, USA
Jackson Memorial Hospital, Miami, FL, USA.
Ann Pharmacother. 2014 Sep;48(9):1238-1241. doi: 10.1177/1060028014540609. Epub 2014 Jun 23.
For the primary prevention of cardiovascular (CV) disease, aspirin reduces the risk for major vascular events by approximately 15% to 20% with an absolute reduction of approximately 0.1%. Major bleeding occurs at an excess of approximately 2 cases per 1000 patient-years with aspirin therapy. For primary prevention, statin therapy has been shown to reduce the risk of CV events by approximately 30% to 40% with an absolute reduction of 1% to 2%. Rhabdomyolysis is rare, with an incidence of 3.4 cases per 100 000 patient-years. Compared with aspirin, statins have a more favorable risk-to-benefit profile for primary prevention.
对于心血管（CV）疾病的一级预防，阿司匹林可将主要血管事件的风险降低约15%至20%，绝对风险降低约0.1%。阿司匹林治疗时，每1000患者年中约有2例额外发生大出血。对于一级预防，他汀类药物治疗已显示可将心血管事件风险降低约30%至40%，绝对风险降低1%至2%。横纹肌溶解症罕见，发病率为每100000患者年3.4例。与阿司匹林相比，他汀类药物在一级预防方面具有更有利的风险效益比。
